Syed Hussain, MBBS, MSc, MD, FRCP, University of Sheffield and Sheffield Teaching Hospitals NHS Trust, Sheffield, UK, discusses the results of the phase II NEO-BLADE study, which tested nintedanib with gemcitabine and cisplatin in patients with locally advanced muscle invasive bladder cancer. The data showed that nintedanib was well tolerated, with an overall improvement in progression-free survival and overall survival. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.